News - 02 Jul `20Vitiligo drug candidate goes to the finals of The Nature Spinoff Prize

New

Temprian Therapeutics, a spinoff from Northwestern University with patent for DNA-based vitiligo treatment, has made it to the finals of the Nature Spinoff Prize.

The 12 finalists represent companies from the United States, United Kingdom, Switzerland and Spain operating in pharmaceuticals, predictive assays and medical devices. Temprian’s selection as a finalist for the Nature Spinoff Prize provides hope for securing investment needed for a clinical trial. 

The judges will select four companies to participate in a live slam on 13 July. The winner will be awarded the title of 2020 Nature Spin-off Prize champion — and a grant of €30,000 (about US$34,000).

Details of Temprian’s innovation and its underlying patent Mutant HSP70i to Prevent Autoimmune Disease.

 



      FAQOther Questions

      • Vitiligo and hearing loss: any connection?

        Vitiligo is primarily recognized for causing skin discoloration, but it can also impact melanocytes in unexpected areas, such as the inner ear. This raises questions about wheth...

      • Isn't it just a cosmetic disorder?

        Contrary to popular belief, vitiligo is not merely a cosmetic issue but a complex autoimmune disorder that affects the body’s largest organ—along with other vital systems—and is...

      • What is the best therapy for localized vitiligo?

        Localized vitiligo, where the white patches are limited to one or a few areas of the body, can be managed with a few treatment approaches. The best therapy usually depends on th...